Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Physiogel (marketed as Fisiogel in Latin America) is a line of hypoallergenic dermo-cosmetic products designed to repair and strengthen the skin's moisture barrier. The formulation utilizes **BioMimic Technology**, which incorporates essential lipids such as ceramides, squalene, and triglycerides that are structurally similar to those found naturally in the skin. By mimicking the skin's natural lipid structure, it helps to restore the skin barrier and reduce transepidermal water loss. It is widely used as an emollient for the management of dry, sensitive skin and inflammatory conditions such as atopic dermatitis, allergic contact dermatitis, and seborrheic dermatitis. Additionally, it has been studied for the prophylaxis and treatment of skin rashes associated with EGFR inhibitor therapies like erlotinib (Tarceva). The brand was originally developed by Stiefel Laboratories, later acquired by GSK, and regional rights were subsequently divested to companies including LG Household & Health Care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Physiogel.